MedTrace Logo

Characteristics and Outcomes of Patients Who Received Etravirine and/or Darunavir

NCT04194021 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 871

Last updated 2023-04-18

No results posted yet for this study

Summary

The objectives of this data collection activity are to:

1. Describe the baseline demographics, clinical and laboratory profile of patients who ever received darunavir (DRV) and/or etravirine (ETR), at the time of initiation on DRV and/or ETR;
2. Describe the clinical and laboratory profile of patients who ever received DRV and/or ETR every 6 months from the first data collection point through 2021;
3. Describe dynamics in HIV drug resistance mutations among patients who fail treatment on new regimens including DRV and/or ETR;
4. Describe demographics, clinical and laboratory profile of young adults who transition out of the donation program after the age of 25 years at 12 months after their transition.

Conditions

Sponsors & Collaborators

  • Janssen, LP

    collaborator INDUSTRY

  • Elizabeth Glaser Pediatric AIDS Foundation

    lead OTHER

Principal Investigators

  • Appolinaire Tiam, MBChB, MMed · Elizabeth Glaser Pediatric AIDS Foundation

Eligibility

Max Age
25 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2019-01-01
Primary Completion
2022-12-31
Completion
2023-12-31

Countries

  • Cameroon
  • Eswatini
  • Kenya
  • Lesotho
  • Uganda

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04194021 on ClinicalTrials.gov